Q2 2025 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2025-08-14 · accession 0000950123-25-008431
$577.2M
Reported value
44
Positions
2025-06-30
Period end
The Brief · MPM BioImpact LLC · Q2 2025
AI · grounded in 13F
MPM BioImpact LLC established a new position in Cullinan Therapeutics, Inc. CGEM valued at $57.6M. The fund also initiated new stakes in Madrigal Pharmaceuticals Inc MDGL for $30.4M and Zai Lab Ltd ZLAB for $26.1M. These moves contributed to a total AUM of $577.2M across 44 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 230031106 | CGEM | Cullinan Therapeutics, Inc. | $57.6M | 9.98% | 7,648,268 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals Inc | $30.4M | 5.27% | 100,415 | Common | SOLE |
| 98887Q104 | ZLAB | Zai Lab Ltd | $26.1M | 4.51% | 745,060 | Common | SOLE |
| 40131M109 | GH | Guardant Health Inc | $23.0M | 3.99% | 442,656 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals Inc | $22.7M | 3.94% | 1,303,399 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $22.6M | 3.91% | 1,720,741 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $21.6M | 3.74% | 760,022 | Common | SOLE |
| 69366J200 | PTCT | PTC Therapeutics Inc | $21.4M | 3.71% | 438,477 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $18.6M | 3.23% | 3,406,955 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $17.6M | 3.04% | 1,729,378 | Common | SOLE |
| 632307104 | NTRA | Natera Inc | $16.7M | 2.90% | 98,924 | Common | SOLE |
| G01767105 | ALKS | Alkermes Plc | $15.7M | 2.72% | 549,262 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $14.8M | 2.56% | 313,571 | Common | SOLE |
| 55287L101 | MBX | MBX Biosciences Inc | $14.8M | 2.56% | 1,294,416 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $14.6M | 2.53% | 5,622,505 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $14.4M | 2.49% | 395,700 | Common | SOLE |
| 47103J105 | JANX | Janux Therapeutics Inc | $14.2M | 2.46% | 614,282 | Common | SOLE |
| 87650L103 | TARS | Tarsus Pharmaceuticals Inc | $13.8M | 2.40% | 341,496 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $13.8M | 2.39% | 1,446,361 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc. | $13.3M | 2.30% | 563,075 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc. | $12.3M | 2.14% | 428,975 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $11.6M | 2.01% | 315,722 | Common | SOLE |
| 00972D105 | AKBA | Akebia Therapeutics Inc | $10.5M | 1.82% | 2,889,125 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals, Inc. | $10.1M | 1.76% | 2,378,762 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $10.1M | 1.75% | 323,398 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences PTE LTD | $9.8M | 1.70% | 1,505,262 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies S A | $9.6M | 1.67% | 1,054,504 | Common | SOLE |
| 21077P108 | CNTX | Context Therapeutics Inc | $9.6M | 1.67% | 14,705,882 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals, Inc. | $9.6M | 1.66% | 3,903,081 | Common | SOLE |
| 76029N106 | REPL | Replimune Group Inc | $9.1M | 1.58% | 983,780 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio Inc | $9.0M | 1.56% | 4,622,590 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics Inc | $9.0M | 1.55% | 789,698 | Common | SOLE |
| 83422E204 | SLDB | Solid Biosciences Inc | $8.0M | 1.38% | 1,634,569 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $7.9M | 1.37% | 2,282,680 | Common | SOLE |
| 816212302 | RNAC | Cartesian Therapeutics Inc | $7.1M | 1.23% | 686,007 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $6.8M | 1.18% | 2,953,562 | Common | SOLE |
| 803607100 | SRPT | Sarepta Therapeutics Inc | $5.5M | 0.95% | 321,696 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $4.2M | 0.73% | 50,000 | Common | SOLE |
| 92536C103 | VERUEUR | Veru Inc. | $2.9M | 0.50% | 4,911,948 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $2.6M | 0.45% | 2,408,810 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics Inc | $1.9M | 0.32% | 555,187 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $1.1M | 0.20% | 819,924 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $1.1M | 0.18% | 4,411,821 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx Inc | $2,436 | 0.00% | 37 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.